HCW Biologics Secures Up to $10.0 Million in Debt Financing From Streeterville Capital
HCW Biologics entered into a notes purchase agreement with Streeterville Capital on November 3, 2026, and closed the financing on November 4, 2026. The company received $3.0 million at closing, with a further $7.0 million held in a controlled account subject to conditions, and says it will use the proceeds for clinical development, business development and general corporate purposes. The notes are secured and carry lender redemption rights, default triggers and a 10% prepayment premium, which shareholders should weigh against the added funding.
Key points
- $3.0 million received at closing on November 4, 2026, after $30,000 in transaction costs; a further $7.0 million is deposited in a controlled account subject to conditions
- Promissory Note A-1 of $3.2 million includes a $240,000 original issue discount; Note B of $7.0 million carries no discount; both are due in 24 months, at 8% and 5% interest per annum
- Beginning six months after closing, the lender may redeem up to $125,000 per calendar month on the A-1 Note; the notes are secured by a controlled account, a subsidiary guaranty and a pledge of subsidiary membership interests
- Maxim Group LLC, the placement agent, is to receive a cash fee of 7.0% of gross proceeds
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.